Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Short term Debt (2021 - 2025)

Ascendis Pharma A (ASND) has disclosed Short term Debt for 5 consecutive years, with $446.7 million as the latest value for Q4 2025.

  • Quarterly Short term Debt fell 8.76% to $446.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $446.7 million through Dec 2025, down 8.76% year-over-year, with the annual reading at $446.7 million for FY2025, 8.76% down from the prior year.
  • Short term Debt hit $446.7 million in Q4 2025 for Ascendis Pharma A, down from $489.6 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $489.6 million in Q4 2024 to a low of $8.0 million in Q4 2021.
  • Historically, Short term Debt has averaged $231.3 million across 5 years, with a median of $200.3 million in 2023.
  • Biggest five-year swings in Short term Debt: soared 1587.68% in 2023 and later dropped 8.76% in 2025.
  • Year by year, Short term Debt stood at $8.0 million in 2021, then skyrocketed by 48.28% to $11.9 million in 2022, then soared by 1587.68% to $200.3 million in 2023, then surged by 144.51% to $489.6 million in 2024, then dropped by 8.76% to $446.7 million in 2025.
  • Business Quant data shows Short term Debt for ASND at $446.7 million in Q4 2025, $489.6 million in Q4 2024, and $200.3 million in Q4 2023.